Skip to content

Study · Randomized controlled trial · n = 78 · 2021

3 results

Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial.

Maagensen H, Larsen JR, Jørgensen NR, Fink-Jensen A, Vilsbøll T

Psychiatry research26 Dec 2020Cited by 15 (Europe PMC)

PMID33373806 (opens in a new tab)DOI10.1016/j.psychres.2020.113670 (opens in a new tab)PepBankPUB-33373806
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In overweight adults with schizophrenia and prediabetes treated with clozapine or olanzapine, 16 weeks of liraglutide did not change P1NP compared with placebo.

    In plain wordsIn overweight adults with schizophrenia and prediabetes, liraglutide did not change a bone formation marker (P1NP) compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeP1NP (bone formation marker)
    Study

    n = 78

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    After 16 weeks of treatment, no significant changes of neither P1NP nor CTX were observed when comparing liraglutide to placebo.
    1 context sentence
    Summary · context
    Patients diagnosed with a schizophrenia spectrum disorder treated with the antipsychotic compounds clozapine and/or olanzapine, having prediabetes and a BMI above 27 kg/m2 were randomized to 16 weeks of treatment with liraglutide or placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In overweight adults with schizophrenia and prediabetes treated with clozapine or olanzapine, 16 weeks of liraglutide did not change CTX compared with placebo.

    In plain wordsIn overweight adults with schizophrenia and prediabetes, liraglutide did not change a bone breakdown marker (CTX) compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeCTX (bone resorption marker)
    Study

    n = 78

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    After 16 weeks of treatment, no significant changes of neither P1NP nor CTX were observed when comparing liraglutide to placebo.
    1 context sentence
    Summary · context
    Patients diagnosed with a schizophrenia spectrum disorder treated with the antipsychotic compounds clozapine and/or olanzapine, having prediabetes and a BMI above 27 kg/m2 were randomized to 16 weeks of treatment with liraglutide or placebo.
  3. 03HumanRandomized controlled trialMechanism

    In the liraglutide group, changes in bone turnover markers were not associated with changes in body weight.

    In plain wordsIn people given liraglutide, changes in bone markers were not linked to changes in body weight.

    Peptide
    Liraglutide
    Outcome
    No significant changeAssociation of bone marker change with body weight change
    Study

    n = 78

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    No association between changes of bone turnover markers and change of body weight were found in the group treated with liraglutide.
    1 context sentence
    Summary · context
    Patients diagnosed with a schizophrenia spectrum disorder treated with the antipsychotic compounds clozapine and/or olanzapine, having prediabetes and a BMI above 27 kg/m2 were randomized to 16 weeks of treatment with liraglutide or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.